Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
South Korea
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do Seoul National University Hospital, Seoul, KR Severance Hospital, Seoul, KR Asan Medical Center, Seoul, KR Korea University Anam Hospital, Seoul